iShares iBonds 2031年12月期市政债券ETF IBMT 深 沪
等待开盘 05-21 09:30:00 美东时间
25.57
+0.060
+0.24%
华盛通- 最 高25.595
- 今 开25.55
- 成交量 1.56万股
- 最 低 25.5322
- 昨 收 25.51
- 总市值 8949.50万
- 52周最高 26.2807
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 24.5054
- 委 比 -17.70%
- 总股本 350.00万
- 历史最高 26.2807
- 量 比 1.14
- 振 幅 0.25%
- 历史最低 23.5818
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Citius Oncology reports positive Phase 1 topline data for LYMPHIR before CAR-T in high-risk DLBCL
Citius Oncology reports positive Phase 1 topline data for LYMPHIR before CAR-T in high-risk DLBCL Citius Oncology Inc. reported preliminary topline safety and efficacy data from an investigator-initiated Phase 1 trial evaluating LYMPHIR (E7777, denileukin diftitox-cxdl) administered prior to commerc
03-04 22:15
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Mesoblast shares fall after new Ryoncil data show high survival in severe GVHD. Company plans adult trial as analysts keep Hold rating and stock trades near key levels.
02-12 21:11
CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme™ test for hematologic cancer relapse detection will be presented
02-03 20:05
CareDx kündigt Präsentation klinischer Validierungsdaten zum AlloHeme-Test zur Rückfallüberwachung bei Blutkrebspatienten an
CareDx kündigt Präsentation klinischer Validierungsdaten zum AlloHeme-Test zur Rückfallüberwachung bei Blutkrebspatienten an CareDx Inc. hat angekündigt, dass die vollständigen 24-Monats-Ergebnisse der klinischen Validierungsstudie ACROBAT zu AlloHeme™, einem KI-basierten Bluttest zur Überwachung vo
02-03 20:05
Artiva Biotherapeutics to Present Data on AlloNK Cost-Effectiveness and Durability at Tandem Meetings
Artiva Biotherapeutics to Present Data on AlloNK Cost-Effectiveness and Durability at Tandem Meetings Artiva Biotherapeutics Inc. will present at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), taking place from February 4 to 7, 2026, in Salt Lake City, Ut
01-21 21:01
Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data
Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data Artiva Biotherapeutics Inc. announced upcoming presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for February 4-7, 2026, in Salt Lake City, Utah. T
01-21 21:00
BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101
Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O: BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS OF ASTCT AND CIBMTR So...
2025-01-23 20:01
